In the subgroup analyses by baseline metastatic status, the estimates for FFS in SOC + ZA + Cel were HR, 0.77 (95% CI, 0.63 to 0.93) in metastatic disease and HR, 1.02 (95% CI, 0.75 to 1.39) in nonmetastatic disease, but there was no evidence of heterogeneity (P = .119). Here, UBXN11 is linked to metastatic neoplasm.